Aggressive Cholesterol Therapy to Inhibit Vein Graft Events (ACTIVE Trial): High-Dose Statin Therapy after CABG

Project: Research


  • Alexander Kulik (PI)


Because of its ease of use and ready availability, the saphenous vein is the most commonly utilized conduit during coronary artery bypass graft surgery (CABG). While convenient as a conduit however, the saphenous vein is severely limited by the development of saphenous vein graft (SVG) disease, a process influenced by hyperlipidemia. Developing in the months that follow surgery, SVG disease begins with intimal hyperplasia, a thickening of the inner lining of the vein resulting from smooth muscle cell proliferation. Intimal hyperplasia forms a template for the development of SVG atherosclerosis leading to eventual graft stenosis and occlusion. Up to 20% of SVGs occlude within the first year after bypass surgery, and by 10 years after surgery, only 60% of SVGs remain patent. As a result of graft attrition, patients who have undergone CABG are at high risk for subsequent ischemic events.Statins have been shown in laboratory experiments to inhibit SVG intimal hyperplasia. Several clinical studies have also demonstrated that lipid-lowering agents reduce the incidence of postoperative myocardial events and graft occlusions after CABG. Based on data published more than 10 years ago, the current AHA/ACC guidelines recommend statin treatment to achieve LDL levels
Award amount$165,000.00
Award date07/01/2012
Program typeGrant-in-Aid
Award ID12GRNT12050027
Effective start/end date07/01/201206/30/2014